ARTICLE | Regulation
New SOC in sickle cell?
How Emmaus’ Endari could form the backbone of future sickle cell therapy
June 9, 2017 6:34 PM UTC
If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc., the candidate is likely to become the backbone of sickle cell therapy.
On May 24, FDA’s Oncologic Drugs Advisory Committee voted 10-3 to support approval of Endari to treat sickle cell disease...